TY - JOUR
T1 - Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly
T2 - the SCIENCe project
AU - Verberk, Inge M.W.
AU - Hendriksen, Heleen M.A.
AU - van Harten, Argonde C.
AU - Wesselman, Linda M.P.
AU - Verfaillie, Sander C.J.
AU - van den Bosch, Karlijn A.
AU - Slot, Rosalinde E.R.
AU - Prins, Niels D.
AU - Scheltens, Philip
AU - Teunissen, Charlotte E.
AU - Van der Flier, Wiesje M.
N1 - Copyright © 2020 Elsevier Inc. All rights reserved.
PY - 2020/5
Y1 - 2020/5
N2 - Plasma biomarkers are promising prognostic tools in individuals with subjective cognitive decline (SCD). We aimed to investigate the relationships of baseline plasma amyloid beta (Aβ)42/Aβ40 and total Tau (tTau) with rate of cognitive decline, in comparison to relationships of baseline cerebrospinal fluid (CSF) Aβ42, tTau, and phosphorylated tau181 (pTau181) with rate of cognitive decline. We included 241 subjects with SCD (age = 61 ± 9, 40% female, Mini-Mental State Examination = 28 ± 2) with follow-up (average: 2 ± 2 years, median visits: 3 [range: 1–11]) for re-evaluation of neuropsychological test performance (attention, memory, language, and executive functioning domains). Using age, gender and education-adjusted linear mixed models, we found that lower plasma Aβ42/Aβ40 was associated with steeper rate of decline on tests for attention, memory, and executive functioning, but not language. Lower CSF Aβ42 was associated with steeper decline on tests covering all domains. Associations for plasma amyloid and cognitive decline mirror those of CSF amyloid. Plasma tTau was not associated with rate of cognitive decline, whereas CSF tTau and pTau181 were on multiple tests covering all domains.
AB - Plasma biomarkers are promising prognostic tools in individuals with subjective cognitive decline (SCD). We aimed to investigate the relationships of baseline plasma amyloid beta (Aβ)42/Aβ40 and total Tau (tTau) with rate of cognitive decline, in comparison to relationships of baseline cerebrospinal fluid (CSF) Aβ42, tTau, and phosphorylated tau181 (pTau181) with rate of cognitive decline. We included 241 subjects with SCD (age = 61 ± 9, 40% female, Mini-Mental State Examination = 28 ± 2) with follow-up (average: 2 ± 2 years, median visits: 3 [range: 1–11]) for re-evaluation of neuropsychological test performance (attention, memory, language, and executive functioning domains). Using age, gender and education-adjusted linear mixed models, we found that lower plasma Aβ42/Aβ40 was associated with steeper rate of decline on tests for attention, memory, and executive functioning, but not language. Lower CSF Aβ42 was associated with steeper decline on tests covering all domains. Associations for plasma amyloid and cognitive decline mirror those of CSF amyloid. Plasma tTau was not associated with rate of cognitive decline, whereas CSF tTau and pTau181 were on multiple tests covering all domains.
KW - Aged
KW - Amyloid beta-Peptides/blood
KW - Biomarkers/blood
KW - Cognition
KW - Cognitive Dysfunction/diagnosis
KW - Executive Function
KW - Female
KW - Follow-Up Studies
KW - Healthy Aging/psychology
KW - Humans
KW - Male
KW - Middle Aged
KW - Neuropsychological Tests
KW - Peptide Fragments/blood
KW - tau Proteins/blood
UR - http://www.scopus.com/inward/record.url?scp=85079535003&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2020.01.007
DO - 10.1016/j.neurobiolaging.2020.01.007
M3 - Article
C2 - 32081465
AN - SCOPUS:85079535003
SN - 0197-4580
VL - 89
SP - 99
EP - 107
JO - Neurobiology of Aging
JF - Neurobiology of Aging
ER -